Solu-Medrol

Stevens-Johnson Syndrome, Pemphigus, Ophthalmia, Sympathetic + 45 more

Treatment

5 FDA approvals

20 Active Studies for Solu-Medrol

What is Solu-Medrol

Methylprednisolone hemisuccinate

The Generic name of this drug

Treatment Summary

Methylprednisolone is a type of steroid medication that is more powerful than prednisone. It was approved by the FDA in 1957 and is currently being studied as a potential treatment for COVID-19-associated pneumonia in those with weakened immune systems. Clinical trials are underway to determine the efficacy of methylprednisolone in treating this virus.

Solu-medrol

is the brand name

image of different drug pills on a surface

Solu-Medrol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Solu-medrol

Methylprednisolone hemisuccinate

1959

89

Approved as Treatment by the FDA

Methylprednisolone hemisuccinate, also known as Solu-medrol, is approved by the FDA for 5 uses including Tuberculosis, Pulmonary and Tuberculosis, Pulmonary .

Tuberculosis, Pulmonary

Used to treat disseminated Pulmonary Tuberculosis (TB) in combination with null

Tuberculosis, Pulmonary

Used to treat fulminating Pulmonary Tuberculosis in combination with null

Tuberculous Meningitis

Used to treat Tuberculous Meningitis in combination with null

Tuberculosis, Meningeal

Used to treat Tuberculous Meningitis in combination with null

Subarachnoid Block

Used to treat Subarachnoid Block in combination with null

Effectiveness

How Solu-Medrol Affects Patients

Corticosteroids help reduce inflammation by binding to the glucocorticoid receptor. They are often given in doses that are much higher than what the body would normally produce. Taking corticosteroids can lead to a decreased ability to fight off infections and other issues, so it's important to be aware of these risks before starting treatment.

How Solu-Medrol works in the body

Corticosteroids help reduce swelling and inflammation in the body. They do this by changing gene expression, preventing white blood cells from moving to sites of inflammation, and reducing the production of substances that cause inflammation. Lower doses are anti-inflammatory, while higher doses are immunosuppressive. Long-term, high doses of corticosteroids can raise sodium levels and lower potassium levels.

When to interrupt dosage

The recommended dosage of Solu-Medrol is contingent upon the identified condition, including Inflammation, Necrobiosis lipoidica diabeticorum and Diuresis. The dosage quantity oscillates, commensurate with the administration technique outlined in the table beneath.

Condition

Dosage

Administration

Mycosis Fungoides

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Polymyositis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Addison Disease

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Eosinophilic Pneumonia

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Dermatitis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Multiple Sclerosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Trichinosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Thrombocytopenia

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Sarcoidosis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Acute Coryza

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Anemia, Hemolytic

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Craniotomy

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Thyroiditis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

exfoliative erythroderma

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

induction of Diuresis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Diuresis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Arthritis, Gouty

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Giant Cell Arteritis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Brain

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Dermatomyositis

, 40.0 mg/mL, 125.0 mg/mL, 1000.0 mg, 40.0 mg, 100.0 mg/mL, 125.0 mg, 500.0 mg/mL, 1000.0 mg/mL, 500.0 mg, 2000.0 mg, 200.0 mg/mL, 5000.0 mg

, Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Intramuscular; Intravenous; Rectal, Powder, for solution - Intramuscular; Intravenous; Rectal, Intracavernous; Intramuscular, Injection, powder, for solution - Intracavernous; Intramuscular, Injection, Injection - Intramuscular; Intravenous, Kit; Powder, for solution - Intramuscular; Intravenous, Kit; Powder, for solution, Kit; Powder - Intramuscular; Intravenous, Powder, for solution - Intramuscular; Intravenous, Kit; Powder

Warnings

Solu-Medrol Contraindications

Condition

Risk Level

Notes

intrathecal administration

Do Not Combine

Mycoses

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methylprednisolone Hemisuccinate may interact with Pulse Frequency

There are 20 known major drug interactions with Solu-Medrol.

Common Solu-Medrol Drug Interactions

Drug Name

Risk Level

Description

Aldesleukin

Major

The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Methylprednisolone hemisuccinate.

Corticorelin ovine triflutate

Major

The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone hemisuccinate.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Methylprednisolone hemisuccinate.

1,10-Phenanthroline

Minor

The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Methylprednisolone hemisuccinate.

Aceclofenac

Minor

The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone hemisuccinate is combined with Aceclofenac.

Solu-Medrol Toxicity & Overdose Risk

The toxic dose of glucocorticoids in rats is more than 4g/kg. In mice, the toxic dose is 2292mg/kg, and in rats it is 100mg/kg. If a person takes a large amount of glucocorticoids chronically, they may experience cataracts, glaucoma, high blood pressure, water retention, high cholesterol, ulcers, pancreatitis, muscle weakness, mood changes, psychosis, thinning skin, allergies, acne, increased body hair, lowered immunity, moon face, high blood sugar, low calcium or phosphate levels, acidosis, stunted growth,

image of a doctor in a lab doing drug, clinical research

Solu-Medrol Novel Uses: Which Conditions Have a Clinical Trial Featuring Solu-Medrol?

594 active clinical trials are currently examining the potential of Solu-Medrol to mitigate Asthma, Atopic Dermatitis and Ulcerative Colitis.

Condition

Clinical Trials

Trial Phases

Metastatic Brain Tumors

56 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1, Phase 4

Psoriatic Arthritis

30 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Phase 4, Phase 2

Ulcerative Colitis

14 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1

Thrombocytopenia

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Berylliosis

0 Actively Recruiting

Adrenal Insufficiency

0 Actively Recruiting

Diuresis

0 Actively Recruiting

Anemia, Hemolytic

0 Actively Recruiting

Brain

0 Actively Recruiting

Brain

7 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Lupus Erythematosus

3 Actively Recruiting

Phase 4, Phase 1, Not Applicable

Crohn Disease

0 Actively Recruiting

Subarachnoid Block

0 Actively Recruiting

Stevens-Johnson Syndrome

1 Actively Recruiting

Phase 1

exfoliative erythroderma

0 Actively Recruiting

Arthritis, Gouty

0 Actively Recruiting

Multiple Sclerosis

0 Actively Recruiting

Craniotomy

0 Actively Recruiting

Addison Disease

0 Actively Recruiting

Solu-Medrol Reviews: What are patients saying about Solu-Medrol?

5

Patient Review

8/21/2013

Solu-Medrol for Rheumatoid Arthritis

Solumedral has been an absolute wonder drug for me. I was experiencing debilitating side effects from Taxol and Carbo Platin, but this medication (along with a few others) have almost completely alleviated them.

5

Patient Review

4/18/2013

Solu-Medrol for Allergic Reaction caused by a Drug

I didn't notice any difference.

4.7

Patient Review

1/17/2014

Solu-Medrol for Multiple Sclerosis

I had an allergic reaction and used my EpiPen. I went to the ER and they gave me IV Benadryl and Solu-Medrol. The Solu-Medrol made me so anxious that I had tachycardia. I felt awful. I was stuck in the ER for 5 hours until the tachycardia subsided.

4.7

Patient Review

4/2/2017

Solu-Medrol for Eye Disorder

I experienced some serious side effects while using this medication, but it was effective in reducing the inflammation in my eyes. I no longer have double vision and have recovered most of the mobility in my eyes.

4.3

Patient Review

8/20/2014

Solu-Medrol for Multiple Sclerosis

It's easy for me to administer this treatment; the home health nurse starts it when I receive the first dose. I have a port because I have another blood condition which requires monthly IV infusions. This isn't my first time dealing with this, so I'm familiar with the process and not too worried. My blood pressure is going up, but that might just be because I'm in severe pain right now.

4.3

Patient Review

9/12/2013

Solu-Medrol for Allergic Reaction caused by a Drug

The only issue I had was that it made it difficult for me to sleep; other than that, great results.

4

Patient Review

7/11/2014

Solu-Medrol for Multiple Sclerosis

The monthly IV treatment for my Dermatomyositis has allowed me to walk without stumbling or falling. I'm grateful that we found this option, as it is less invasive than other options (e.g. daily steroid prescriptions) and the positive effects last for almost a month.

4

Patient Review

11/6/2012

Solu-Medrol for Joint Disease which may include Attacks of Acute Arthritis

Though the treatments themselves were easy enough, I've been struggling with some nasty side effects like low blood pressure, weakness and fatigue. I'm just hoping these will pass soon.

4

Patient Review

5/9/2013

Solu-Medrol for Multiple Sclerosis

I have Familial Mediterranean Fever and this medication really helps me a lot when I need to stop a flare-up. The side effects can be intense for me, but the results are worth it.

4

Patient Review

12/21/2016

Solu-Medrol for Eye Disorder

This solumedrol really helped with the inflammation in my eye that prednisone couldn't touch. The swelling is gone now, but my vision is still a bit impaired. The only other downside was a headache and slightly higher blood pressure, but those were manageable.

3.7

Patient Review

9/4/2015

Solu-Medrol for Acute Exacerbation of Multiple Sclerosis

I had this infusion done through a port and it was very effective. I only experienced some soreness in my tongue and throat, which may or may not be related to the treatment.

3.7

Patient Review

8/5/2015

Solu-Medrol for Multiple Sclerosis

I experienced some soreness, gastrointestinal issues, and my tongue felt raw after taking this medication.

2.7

Patient Review

7/29/2012

Solu-Medrol for Multiple Sclerosis

2

Patient Review

11/3/2012

Solu-Medrol for Multiple Sclerosis

1.3

Patient Review

11/25/2016

Solu-Medrol for Thyroid Gland Inflammation

My face swells up easily. I can't eat yogurt.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about solu-medrol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does Solu-Medrol take to work?

"The medicine will have an effect 6 to 48 hours after it is injected into a muscle. Its effect will be noticeable sooner if it is injected into a vein."

Answered by AI

Is Solu-Medrol the same as prednisone?

"A lower dosage of methylprednisolone is used because it is slightly stronger than prednisone."

Answered by AI

What is Solu-Medrol used for?

"This medication can help to relieve symptoms associated with different medical conditions, including arthritis, blood disorders, severe allergies, certain types of cancer, eye conditions, and skin, kidney, intestinal, and lung diseases. It can also be used to help improve the function of the immune system."

Answered by AI

Is Solu-Medrol a steroid?

"The drug also acts as an immunosuppressant, and is used in the preventative treatment of organ transplantation.

Solu-Medrol is a man-made steroid. It is used to treat severe allergies, skin diseases, hormone disorders, gut diseases, and joint diseases. It also suppresses the immune system, and is used to prevent organ transplant rejection."

Answered by AI

Clinical Trials for Solu-Medrol

Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Have you considered Solu-Medrol clinical trials?

We made a collection of clinical trials featuring Solu-Medrol, we think they might fit your search criteria.
Go to Trials
Image of UCSF Medical Center in San Francisco, United States.

Upadacitinib for Ulcerative Colitis

18 - 75
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if the oral medication upadacitinib can safely and effectively treat acute severe ulcerative colitis (ASUC) in adults who are hospitalized. It will also evaluate whether upadacitinib can be used without corticosteroids during initial treatment. The main questions it aims to answer are: 1. Does upadacitinib reduce treatment failure by Day 14 (defined as need for colectomy or rescue therapy)? 2. What side effects and safety events occur when using upadacitinib in hospitalized patients with ASUC? Researchers will compare outcomes in participants receiving upadacitinib to a historical group of similar patients previously treated with standard therapies, including intravenous corticosteroids and infliximab, to determine if upadacitinib improves outcomes. Participants will: 1. Take oral upadacitinib once daily during hospitalization. 2. Undergo routine clinical monitoring, including blood tests and symptom assessments. 3. Be followed after discharge with clinic visits or phone calls for up to 12 months to assess outcomes such as need for additional treatment, surgery, and safety events

Phase 4
Waitlist Available

UCSF Medical Center

Sara Lewin, MD

AbbVie

Image of Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120) in Tucson, United States.

Tulisokibart for Psoriatic Arthritis

18 - 80
All Sexes
Tucson, AZ

Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen PsA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Phase 2
Recruiting

Arizona Arthritis & Rheumatology Associates, P.C. - Tucson ( Site 5120) (+5 Sites)

Medical Director

Merck Sharp & Dohme LLC

Have you considered Solu-Medrol clinical trials?

We made a collection of clinical trials featuring Solu-Medrol, we think they might fit your search criteria.
Go to Trials
Image of Wallace & Lee Center in Beverly Hills, United States.

BI 3000202 for Lupus

18 - 74
All Sexes
Beverly Hills, CA

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.

Phase 2
Recruiting

Wallace & Lee Center (+28 Sites)

Boehringer Ingelheim

Have you considered Solu-Medrol clinical trials?

We made a collection of clinical trials featuring Solu-Medrol, we think they might fit your search criteria.
Go to Trials